Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Aurobindo Pharma
Pharma
Padcev-Keytruda result, Alzheimer's med, Fosun—Fierce Pharma Asia
The Padcev-Keytruda combo notched another phase 3 win. China didn't renew an Alzheimer's drug's conditional nod. Fosun out-licensed a DPP1 inhibitor.
Angus Liu
Aug 15, 2025 8:31am
Aurobindo acquires US drugmaker Lannett for $250M
Aug 7, 2025 9:35am
Trump's tariffs, Leqembi, Kyowa Kirin—Fierce Pharma Asia
Apr 18, 2025 9:25am
Aurobindo discloses FDA Form 483 at North Carolina inhaler plant
Apr 14, 2025 3:00pm
Drugmakers Aurobindo, Glenmark and Zydus issue voluntary recalls
Dec 18, 2024 12:13pm
J&J-Yuhan, Merck, biosecurity—Fierce Pharma Asia
Aug 23, 2024 10:05am
